The Application Value of Deep Learning-Based Nomograms in Benign-Malignant Discrimination of TI-RADS Category 4 Thyroid Nodules

February 5, 2024 updated by: Ma Zhe

This retrospective study focuses on benign and malignant classification of thyroid nodules using deep learning techniques and evaluates the value of deep learning based nomograms in the classification of TI-RADS category 4 thyroid nodules to improve the accuracy of benign and malignant identification of TI-RADS category 4 thyroid nodules.

Materials and methods: Patients who visited in The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital were collected. Their general clinical features, information on preoperative ultrasound diagnosis, and postoperative pathologic data were reviewed.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shandong
      • Jinan, Shandong, China
        • QianfoshanH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study collected data on a total of 500 TI-RADS category 4 thyroid nodules from 500 patients who attended the First Affiliated Hospital of Shandong First Medical University from April 2022 to November 2023.

Description

Inclusion Criteria:

  1. Ultrasound-confirmed diagnosis of thyroid nodules that are classified as TI-RADS category 4.
  2. Availability of pathological results.

Exclusion Criteria:

  1. Lack of pathological diagnosis.
  2. History of thyroid surgery or other treatments.
  3. Poor quality of ultrasound images of thyroid nodules.
  4. Incomplete clinical and imaging data of the patient.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
maligant
Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of malignancy in the TI-RADS4 category
benign
Thyroid nodules with surgical or puncture biopsy-confirmed pathological findings of benign TI-RADS4 category

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
deep learning prediction model(YOLOv3) and the model evaluation
Time Frame: Immediately evaluated after the prediction model was built
Based on the characteristics of benign and malignant thyroid nodules, the dataset was divided into a training set and a test set using the cross-validation method, and the YOLOv3 model was trained using data from the training set, and the performance of the model was evaluated using data from the test set.The model is evaluated using a number of metrics such as: precision-recall curve, effective classification precision, confusion matrix and area under the curve.
Immediately evaluated after the prediction model was built
nomogram prediction and assessment
Time Frame: Immediately evaluated after the nomogram was built
Factoring clinical features, ultrasound grading and model predictions to map nomograms using R language.Evaluation of the nomogram using various metrics, including subject operating characteristic curves, calibration curves and decision curve analysis
Immediately evaluated after the nomogram was built
Selection of clinical features and assessment
Time Frame: After the dataset is collected and pathology results are obtained, the statistical results obtained are analyzed for clinical factors, averaging about 1 year.
The researchers selected patients with TI-RADS category 4 thyroid nodules within 1 year to comprise the dataset. The researchers analyzed the clinical factors in the dataset and analyzed the significance of these clinical factors on the statistical results and clinical characteristics using the Wilcoxon two-sample rank sum test or chi-square test.
After the dataset is collected and pathology results are obtained, the statistical results obtained are analyzed for clinical factors, averaging about 1 year.
Impact and assessment of ultrasound grading
Time Frame: The graded results of the ultrasound examination were analyzed after the data set collection was completed, the ultrasound examination was completed and the final pathology results were obtained, on average about 1 year.
The researchers selected patients with TI-RADS category 4 thyroid nodules within 1 year to comprise the dataset. The researchers analyzed the results of grading TI-RADS category 4 nodules in this dataset and determined the significance of ultrasound grading on the statistical results using the chi-square test.
The graded results of the ultrasound examination were analyzed after the data set collection was completed, the ultrasound examination was completed and the final pathology results were obtained, on average about 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2022

Primary Completion (Actual)

November 30, 2023

Study Completion (Actual)

November 30, 2023

Study Registration Dates

First Submitted

January 4, 2024

First Submitted That Met QC Criteria

February 5, 2024

First Posted (Actual)

February 14, 2024

Study Record Updates

Last Update Posted (Actual)

February 14, 2024

Last Update Submitted That Met QC Criteria

February 5, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thyroid Nodule

Subscribe